- Home
- PYXS vs VRCA Comparison
PYXS vs VRCA Comparison
Compare PYXS & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- VRCA
- Stock Information
- Founded
- PYXS 2018
- VRCA 2013
- Country
- PYXS United States
- VRCA United States
- Employees
- PYXS N/A
- VRCA N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- VRCA Health Care
- Exchange
- PYXS Nasdaq
- VRCA Nasdaq
- Market Cap
- PYXS 76.1M
- VRCA 66.7M
- IPO Year
- PYXS 2021
- VRCA 2018
- Fundamental
- Price
- PYXS $1.28
- VRCA $0.74
- Analyst Decision
- PYXS Strong Buy
- VRCA Hold
- Analyst Count
- PYXS 6
- VRCA 5
- Target Price
- PYXS $9.20
- VRCA $6.00
- AVG Volume (30 Days)
- PYXS 551.2K
- VRCA 222.4K
- Earning Date
- PYXS 03-20-2025
- VRCA 03-03-2025
- Dividend Yield
- PYXS N/A
- VRCA N/A
- EPS Growth
- PYXS N/A
- VRCA N/A
- EPS
- PYXS N/A
- VRCA N/A
- Revenue
- PYXS $16,146,000.00
- VRCA $9,210,000.00
- Revenue This Year
- PYXS N/A
- VRCA $64.32
- Revenue Next Year
- PYXS N/A
- VRCA $73.76
- P/E Ratio
- PYXS N/A
- VRCA N/A
- Revenue Growth
- PYXS N/A
- VRCA 187.45
- 52 Week Low
- PYXS $1.23
- VRCA $0.61
- 52 Week High
- PYXS $6.85
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- PYXS 32.91
- VRCA 55.52
- Support Level
- PYXS $1.23
- VRCA $0.69
- Resistance Level
- PYXS $1.40
- VRCA $0.78
- Average True Range (ATR)
- PYXS 0.09
- VRCA 0.05
- MACD
- PYXS 0.00
- VRCA 0.01
- Stochastic Oscillator
- PYXS 15.15
- VRCA 73.07
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.